Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

(2016) Maria Bjerke et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

The confidence level of established cut-off values for CSF Alzheimer's disease-specific biomarkers

(2015) Els Coart et al.   Alzheimers & Dementia

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

(2015) Ju-Hee Kang et al.   Alzheimers & Dementia

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability

(2015) Anthony Fourier et al.   CLINICA CHIMICA ACTA

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

(2015) Sebastian Palmqvist et al.   NEUROLOGY

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

(2015) Julien Dumurgier et al.   Alzheimers Research & Therapy

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease

(2015) Katarzyna Adamczuk et al.   Alzheimers Research & Therapy

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age

(2015) Courtney L. Sutphen et al.   JAMA Neurology

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation

(2015) Claudia Cicognola et al.   Frontiers in Neurology

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Development and Advanced Validation of an Optimized Method for the Quantitation of Aβ42 in Human Cerebrospinal Fluid

(2012) Valerie C. Cullen et al.   AAPS Journal

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases

(2012) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

(2012) Marta del Campo et al.   Biomarkers in Medicine

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

(2011) Hugo Vanderstichele et al.   Alzheimers & Dementia

pROC: an open-source package for R and S+ to analyze and compare ROC curves

(2011) Xavier Robin et al.   BMC BIOINFORMATICS

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers

(2009) Piotr Lewczuk et al.   JOURNAL OF NEURAL TRANSMISSION

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

(2009) Volker Welge et al.   JOURNAL OF NEURAL TRANSMISSION

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

(2009) Karen Koopman et al.   NEUROCHEMISTRY INTERNATIONAL

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

(2009) C. E. Teunissen et al.   NEUROLOGY

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

(2007) Sebastiaan Engelborghs et al.   NEUROBIOLOGY OF AGING